BACKGROUND: Post-infectious autoimmunity and immune deficiency have been implicated in the pathogenesis of Tourette syndrome (TS). We asked here whether B cell immunity of patients with TS differs from healthy subjects. METHODS: In two independent cross-sectional samples, we compared serum levels of IgG1, IgG2, IgG3, IgG4, IgM, IgA, and IgE in 21 patients with TS from Yale University (17 males, 4 females, 8-16 years) versus 21 healthy controls (13 males, 8 females, 7-17 years); and in 53 patients with TS from Groningen University (45 males, 8 females, 6-18 years) versus 53 healthy controls (22 males, 31 females, 6-18 years), respectively. We also investigated correlations between Ig concentrations and symptom severity. In 13 additional patients (9 males, 4 females, age range 9-14), we established Ig profiles at time points before, during, and after symptom exacerbations. RESULTS: IgG3 levels were significantly lower in Yale patients compared to healthy children (medians 0.28 versus 0.49 mg/ml, p=.04), while levels of IgG2, IgG4, and IgM in patients were lower at trend-level significance (p≤.10). Decreased IgG3 (medians 0.45 versus 0.52 mg/ml; p=.05) and IgM (medians 0.30 versus 0.38 mg/ml; p=.04) levels were replicated in the Groningen patients. Ig levels did not correlate with symptom severity. There was a trend-level elevation of IgG1 during symptom exacerbations (p=.09). CONCLUSION: These pilot data indicate that at least some patients with TS have decreased serum IgG3, and possibly also IgM levels, though only few subjects had fully expressed Ig immunodeficiency. Whether these changes are related to TS pathogenesis needs to be investigated.
BACKGROUND: Post-infectious autoimmunity and immune deficiency have been implicated in the pathogenesis of Tourette syndrome (TS). We asked here whether B cell immunity of patients with TS differs from healthy subjects. METHODS: In two independent cross-sectional samples, we compared serum levels of IgG1, IgG2, IgG3, IgG4, IgM, IgA, and IgE in 21 patients with TS from Yale University (17 males, 4 females, 8-16 years) versus 21 healthy controls (13 males, 8 females, 7-17 years); and in 53 patients with TS from Groningen University (45 males, 8 females, 6-18 years) versus 53 healthy controls (22 males, 31 females, 6-18 years), respectively. We also investigated correlations between Ig concentrations and symptom severity. In 13 additional patients (9 males, 4 females, age range 9-14), we established Ig profiles at time points before, during, and after symptom exacerbations. RESULTS:IgG3 levels were significantly lower in Yale patients compared to healthy children (medians 0.28 versus 0.49 mg/ml, p=.04), while levels of IgG2, IgG4, and IgM in patients were lower at trend-level significance (p≤.10). Decreased IgG3 (medians 0.45 versus 0.52 mg/ml; p=.05) and IgM (medians 0.30 versus 0.38 mg/ml; p=.04) levels were replicated in the Groningen patients. Ig levels did not correlate with symptom severity. There was a trend-level elevation of IgG1 during symptom exacerbations (p=.09). CONCLUSION: These pilot data indicate that at least some patients with TS have decreased serum IgG3, and possibly also IgM levels, though only few subjects had fully expressed Ig immunodeficiency. Whether these changes are related to TS pathogenesis needs to be investigated.
Authors: Xinli Du; Yang Tang; Huichun Xu; Lisa Lit; Wynn Walker; Paul Ashwood; Jeffrey P Gregg; Frank R Sharp Journal: Genomics Date: 2006-03-20 Impact factor: 5.736
Authors: J C Möller; B Tackenberg; M Heinzel-Gutenbrunner; R Burmester; W H Oertel; O Bandmann; K R Müller-Vahl Journal: Eur J Neurol Date: 2008-05-15 Impact factor: 6.089
Authors: Ivana Kawikova; James F Leckman; Holger Kronig; Lily Katsovich; Debra E Bessen; Musie Ghebremichael; Alfred L M Bothwell Journal: Biol Psychiatry Date: 2006-09-25 Impact factor: 13.382
Authors: E Kosor Krnic; A Gagro; D Kozaric-Kovacic; M Vilibic; M Grubisic-Ilic; V Folnegovic-Smalc; V Drazenovic; E Cecuk-Jelicic; I Gjenero-Margan; I Kuzman; T Jeren; A Sabioncello; V Kerhin-Brkljacic; B Kaic; A Markotic; K Gotovac; S Rabatic; G Mlinaric-Galinovic; D Dekaris Journal: Clin Exp Immunol Date: 2007-05-18 Impact factor: 4.330
Authors: Jane E Libbey; Hilary H Coon; Nikki J Kirkman; Thayne L Sweeten; Judith N Miller; Edward K Stevenson; Janet E Lainhart; William M McMahon; Robert S Fujinami Journal: J Autism Dev Disord Date: 2007-06-22
Authors: Kiki Chang; Jennifer Frankovich; Michael Cooperstock; Madeleine W Cunningham; M Elizabeth Latimer; Tanya K Murphy; Mark Pasternack; Margo Thienemann; Kyle Williams; Jolan Walter; Susan E Swedo Journal: J Child Adolesc Psychopharmacol Date: 2014-10-17 Impact factor: 2.576
Authors: Jessica B Lennington; Gianfilippo Coppola; Yuko Kataoka-Sasaki; Thomas V Fernandez; Dean Palejev; Yifan Li; Anita Huttner; Mihovil Pletikos; Nenad Sestan; James F Leckman; Flora M Vaccarino Journal: Biol Psychiatry Date: 2014-07-24 Impact factor: 13.382
Authors: Emily A Troyer; Jordan N Kohn; Gertrude Ecklu-Mensah; Gajender Aleti; David R Rosenberg; Suzi Hong Journal: Neurosci Biobehav Rev Date: 2021-02-24 Impact factor: 9.052